IMPORTANT SAFETY INFORMATION

OLUX Foam is a super-potent topical corticosteroid that has been shown to suppress the adrenals at 7.0 g of OLUX Foam per day. Lesser amounts of OLUX Foam were not studied.

Systemic absorption of topical corticosteroids has caused reversible adrenal suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Evaluate patients periodically for evidence of HPA axis suppression.

Cushing's Syndrome, hyperglycemia, and glucosuria can also result from systemic absorption of topical corticosteroids. Use of OLUX Foam for longer than 2 weeks may suppress the immune system.

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. Use in children under 12 years of age is not recommended.

OLUX Foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Caution should be exercised when OLUX Foam is administered to a nursing woman.

In clinical trials, the most common adverse events associated with the use of OLUX Foam were burning, dryness, and other reactions at the application site.

The propellant in this foam is flammable; patients should avoid fire, flame, and/or smoking during and immediately following application.

OLUX Foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older.